Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 5/20 | 0.53 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.53 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.48 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 7/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | ABL2 | P42684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7497533 | 0.90 | BRAF (0.51) | BRAFTNNI3KTTBK1TTBK2EGFR | |
| SCHEMBL7492081 | 0.88 | EGFR (0.58) | BRAFTNNI3KTTBK1TTBK2EGFR | |
| SCHEMBL7497707 | 0.87 | BRAF (0.54) | CYP1A2CYP3A4LMNACYP2D6ALDH1A1 | |
| SCHEMBL7498074 | 0.85 | EGFR (0.57) | BRAFTNNI3KTTBK1TTBK2EGFR | |
| SCHEMBL7494933 | 0.84 | EGFR (0.61) | BRAFTNNI3KTTBK1TTBK2EGFR | |
| SCHEMBL7494298 | 0.84 | BRAF (0.51) | BRAFTNNI3KTTBK1TTBK2EGFR | |
| SCHEMBL4764786 | 0.84 | LMNA (0.56) | LMNAALDH1A1BRAFTNNI3KTTBK1 | |
| SCHEMBL7496028 | 0.83 | NUDT1 (0.57) | CYP1A2CYP3A4LMNACYP2D6ALDH1A1 | |
| SCHEMBL7498606 | 0.83 | BRAF (0.66) | CLK4MAPK1BRAFTNNI3KTTBK1 | |
| SCHEMBL4770048 | 0.83 | EGFR (0.60) | CYP1A2CYP3A4CYP2D6BRAFTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1100778-C | Pyrrolopyrimidines and process for their preparation | NOVARTIS CO (CH) | 2003-02-05 | — | — | CN | claimed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | claimed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | claimed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | claimed |
| US-7390805-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-06-24 | — | — | US | disclosed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-7323469-B2 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | disclosed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | disclosed |
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | BOLD GUIDO | 2007-07-12 | — | — | US | disclosed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | disclosed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | disclosed |
| US-6140332-A | Pyrrolopyrimidines and processes for the preparation thereof | NOVARTIS AG (CH) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | TYMP, DPYD, CCND2 | CYP1A2 410/4885CLK4 3741/4885CYP3A4 382/4885 |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, DHPS, TYMP | CYP1A2 247/4885CLK4 4531/4885CYP3A4 562/4885 |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | CYP1A2 512/4885CLK4 4167/4885CYP3A4 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.